Press Releases

 
Press Releases
  Date Title View
Dec 21, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a U.S.-based Phase 2 clinical trial evaluating CTP-656 (deuterated ivacaftor), a next generation CFTR potentiator being developed for the treatment of cystic fibrosis. CTP-656 was created ba...
Dec 14, 2016
CTP-543 to Advance into Phase 2 in First Quarter of 2017 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers has been completed. Concert is deve...
Nov 8, 2016
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2016. "As we approach the end of the year, our team continues to make progress ...
Nov 1, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2016 financial results on Tuesday, November 8, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EST to discu...
Oct 27, 2016
Clinical Results Demonstrated CTP-656's Features as Potential Next Generation, Once-Daily CFTR Potentiator for Treatment of Cystic Fibrosis LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented a poster describing Phase 1 fo...
Sep 21, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida. Data describing the relative bioavailability of CTP-656...
Sep 6, 2016
Appointment of Two Executives to Support Advancement of Product Pipeline: Christine Boisclair Named Vice President, Regulatory Affairs, and Scott Weintraub Named Vice President, Commercial and Product Strategy LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ...
Sep 1, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2016 Healthcare Conference on September 8, 2016 at 2...
Aug 9, 2016
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2016. "Concert has made significant progress with our pipeline of multiple ...
Aug 2, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2016 financial results on Tuesday, August 9, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discus...
FirstPrevious
3
...
NextLast
= add release to Briefcase